Latest Microarrays Stories
COLOGNE, Germany, and SINGAPORE, September 20, 2012 /PRNewswire/ -- 2.6 million Euro financing will accelerate development of cutting-edge technology for protein analysis AyoxxA Biosystems, an international biotechnology company, today announces it has closed a 2.6 million Euro Series A financing round. The round was led by Wellington Partners Venture Capital and included NRW.BANK, HTGF - High-Tech-Gruenderfonds, and private investors, Rainer Christine and Dr. Gregor...
SAN DIEGO and BERLIN, Sept. 19, 2012 /PRNewswire/ -- Genalyte, Inc., a life sciences company developing and commercializing innovative next generation multiplexing technology, and Scienion AG, a life science company developing microarray and ultra-low volume liquid handling systems, today announced an agreement under which Genalyte will market Scienion's sciFLEXARRAYER(TM)( )automated liquid dispensers along with Genalyte's multiplexed Maverick(TM )Detection System. The...
SAN DIEGO, Sept. 17, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM) today announced the completion of its offering of $130.0 million aggregate principal amount of 5.00% Convertible Senior Notes due 2017 (the "Convertible Notes") in a private offering, including $20.0 million aggregate principal amount of notes sold pursuant to the full exercise of an over-allotment option previously granted to the initial purchasers. Sequenom intends to use the net proceeds from this offering...
AMSTERDAM and IRVINE, Calif., Sept. 13, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, announced today that they will present five posters on genomic research studies in breast cancer at the American Society of Clinical Oncology (ASCO) 2012 Breast Cancer Symposium. The meeting will be held from September 13-15, 2012 at the Marriott Marquis in San Francisco, California. Agendia's Symphony(TM) suite of molecular...
SAN DIEGO, Sept. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Lazard Capital Markets Corporate Access Day in Boston, Mass., and the Credit Suisse 3(rd) Annual Small and Mid-Cap Conference, in New York. On Tuesday, September 18, Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development, will participate in the...
SAN DIEGO, Sept. 5, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Morgan Stanley Global Healthcare Conference, September 10-12, 2012 at the Grand Hyatt in New York. Paul V. Maier, Chief Financial Officer, will present on Wednesday, September 12, 2012, beginning at 9:10 a.m. ET, to provide an overview of and update on the Company....
SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the appointment of Myla Lai-Goldman, M.D., to its Board of Directors, effective September 11, 2012. Dr. Lai-Goldman has also been appointed to the Science Committee of the Company's Board of Directors. Dr. Lai-Goldman is a managing partner at Personalized Science, LLC, and Chief Executive Officer of...
IRVINE, Calif. and AMSTERDAM, Aug. 29, 2012 /PRNewswire/ -- Agendia, an innovative molecular cancer diagnostics company and leader in personalized medicine, conducted one of its premiere thought leadership events, "Present and Future Trends in Breast Cancer Genomics," on Saturday, August 25, 2012. The event was held at The Westin Times Square Hotel in New York City and featured over 200 attendees that included leading medical oncologists, pathologists, surgeons and molecular...
SAN DIEGO, Aug. 28, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that its wholly-owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), has completed several international distribution agreements that will expand access to the MaterniT21 PLUS testing service outside the United States. Agreements in Asia cover Japan and Hong Kong; in Europe...
ORANGE, Calif., Aug. 13, 2012 /PRNewswire/ -- As part of a pilot study designed to advance personalized treatment for children and teens battling recurrent cancer, the Hyundai Cancer Institute at CHOC Children's is the first organization to utilize Illumina's RapidTrack Whole Genome Sequencing (RapidTrack WGS) service for cancer samples. RapidTrack WGS will enable the study to gather whole genome sequencing data in high depth within 14 days, which is the fastest sample-to-data...
